ZenO - FAQ

How ZenO (High-Dissolved Oxygen Therapy) alters the Inflammatory Environment in Hypoxia-Related Diseases

Hypoxia stabilizes HIF‑1α (hypoxia‑inducible factor‑1α), which drives a pro‑inflammatory, pro‑fibrotic, and pro-angiogenic imbalance — promoting inflammation, edema, immune cell dysfunction, and tissue damage.

ZenO reverses this by restoring supraphysiological tissue oxygen tension and normalizing oxygen-dependent signaling pathways.

1. Suppresses Hypoxia-Driven Inflammatory Pathways

Inhibits HIF‑1α stabilization

Reduces transcription of pro-inflammatory cytokines:

TNF‑α, IL‑1β, IL‑6, IFN‑γ

Downregulates NF‑κB (master inflammation switch)

Decreases production of inflammatory chemokines that recruit immune cells

→ Net effect: Less chronic inflammation, less tissue injury.

2. Modulates Immune Cell Phenotype

Shifts M1 macrophages (pro-inflammatory) → M2 macrophages (anti-inflammatory, reparative)

Reduces neutrophil infiltration and oxidative burst

Stabilizes mast cells → less histamine release, less edema

Restores regulatory T‑cell (Treg) function

→ Net effect: Promotes resolution of inflammation instead of amplification.

3. Reduces Oxidative Stress & Damaging Free Radicals

Hypoxia causes reperfusion injury and excessive ROS.

ZenO :

Enhances antioxidant enzymes (SOD, catalase, glutathione)

Prevents lipid peroxidation and mitochondrial damage

Balances ROS production rather than exacerbating it

→ Net effect: Protects cells from oxidative injury.

4. Reduces Vasogenic Edema & Improves Perfusion

Hypoxia increases vascular permeability (via VEGF, bradykinin, etc.).

ZenO:

Constricts dilated, leaky capillaries

Reduces interstitial edema

Improves blood flow by decreasing tissue pressure

Restores perfusion in the “no‑flow” zone around ischemic tissue

→ Net effect: Less swelling, better oxygen and nutrient delivery.

5. Inhibits Fibrosis & Scarring

Hypoxia promotes:

TGF‑β overexpression

Myofibroblast activation

Collagen deposition

ZenO:

Reduces TGF‑β and pro-fibrotic signaling

Limits excessive extracellular matrix accumulation

Prevents pathological fibrosis (e.g., in brain, lung, kidney)

→ Net effect: Preserves tissue structure and function.

6. Restores Mitochondrial Function & Cell Survival

Hypoxia impairs mitochondrial respiration → cell death (apoptosis/necrosis).

ZenO:

Restores oxidative phosphorylation

Reduces hypoxic cell death

Supports ATP production

Enhances stem cell survival and homing

→ Net effect: Tissue repair instead of degeneration.

Is It true? In hypoxia-related diseases, Normal breathing / RBC oxygen cannot reverse hypoxic inflammation — it only sustains baseline metabolism

✅ Why the core claim holds true

In hypoxic‑inflamed tissue (edema, micro‑vascular blockage, scarring): Even with normal arterial saturation (SaO₂ 97‑99%) from room‑air breathing, RBC‑bound oxygen cannot raise tissue PO₂ high enough to shut‑off HIF‑1α, NF‑κB and the downstream pro‑inflammatory transcription program.

RBCs cannot easily penetrate swollen, oedematous, poorly‑perfused micro‑regions.
The small baseline dissolved‑O₂ fraction (~0.3 mL/dL) is insufficient to expand oxygen diffusion distance beyond ~30 μm.
Normal breathing only delivers enough oxygen to support basal cell metabolism; it cannot achieve the supraphysiological tissue PO₂ required to resolve hypoxia‑driven inflammatory signalling.

Room‑air RBC‑borne oxygen prevents cell death from complete anoxia, but does not reverse the pathological hypoxic‑inflammatory molecular state. The HIF‑driven pro‑inflammatory, pro‑fibrotic gene expression remains active in poorly‑perfused tissue.

Notes (more scientifically precise):

In hypoxia‑related diseases characterised by oedema, microvascular obstruction or scarring: normal breathing / RBC‑bound oxygen cannot reverse local hypoxic‑driven inflammation. It can only sustain baseline cellular metabolism, because red blood cells cannot adequately deliver oxygen into poorly‑perfused tissue compartments.

Quick contrast to ZENO

ZENO generates massive dissolved plasma oxygen, extends oxygen diffusion distance to ~100 μm, raises tissue PO₂ enough to degrade HIF‑1α, down‑regulate NF‑κB and resolve hypoxia‑triggered inflammation — even when RBC perfusion is locally impaired.

How does MSCs therapy work in the treatment of hypoxia-related diseases?

MSCs do not mainly work by differentiating and replacing damaged cells. Their dominant therapeutic effect is paracrine signalling, releasing bioactive molecules to remodel the hostile hypoxic‑inflamed microenvironment. In hypoxia‑injured tissues, local low oxygen activates HIF‑1α, driving chronic inflammation, edema, oxidative stress and fibrosis; MSCs counteract these pathological cascades.

1. Immunomodulation & resolving chronic hypoxia‑driven inflammation

Suppress pro‑inflammatory transcription factors NF‑κB and HIF‑1α in host tissue
Reduce pro‑inflammatory cytokines: TNF‑α, IL‑1β, IL‑6
Elevate anti‑inflammatory mediators: IL‑10, TGF‑β
Shift macrophage phenotype: from pro‑inflammatory M1 → reparative M2
Inhibit excessive neutrophil infiltration and their damaging oxidative burst
Stabilize mast‑cell activity to lower edema

Outcome: Stop self‑amplifying inflammatory loops triggered by tissue hypoxia.

2. Paracrine secretion of regenerative factors & exosomes

MSCs secrete a broad panel of growth factors and release extracellular vesicles (exosomes):

VEGF, HGF: improve microvascular angiogenesis, rebuild damaged capillary network
BDNF, NGF: neurotrophic support for neural tissue (stroke, TBI, neurodegeneration)
IGF‑1: reduce cell apoptosis, boost cell survival
MSC‑derived exosomes carry miRNA, proteins and lipids; transfer cargo to injured host cells to restore cellular function.

Critical limitation: Under severe local hypoxia, transplanted MSCs themselves undergo apoptosis, so their paracrine output drops sharply — this is where HBOT / high dissolved oxygen creates strong synergy.

3. Reduce oxidative stress & mitochondrial protection

Up‑regulate host antioxidant systems (SOD, glutathione, catalase)
Mitigate ROS‑mediated reperfusion injury after ischemic insult
Improve mitochondrial function in damaged somatic cells, restore ATP production, reduce necrotic / apoptotic cell death.

4. Anti‑fibrotic effect

Hypoxia drives TGF‑β over‑activation, generating myofibroblasts and pathological scarring.

MSCs down‑regulate TGF‑β signalling
Inhibit myofibroblast activation
Limit excessive collagen deposition, prevent tissue fibrosis (brain, kidney, wound tissue).

5. Promote angiogenesis and microcirculation restoration

Secret angiogenic factors to stimulate new capillary growth
Improve local blood perfusion, gradually relieve tissue hypoxia at source.

Note: This is a slow biological process; angiogenesis takes days‑weeks, cannot immediately reverse acute local hypoxia.

Key limitation of MSC monotherapy

In established hypoxia‑related disease with edema, micro‑vascular blockage and scar tissue:

Transplanted MSCs face a hostile low‑oxygen niche, leading to high MSC death shortly after injection; engraftment rate is typically very low.
Even surviving MSCs cannot instantly raise tissue oxygen tension. They rely on gradual angiogenesis to improve oxygen supply.
Therefore MSCs alone cannot rapidly shut‑down HIF‑1α‑driven pathological signaling.

This explains the synergy with ZENO / high dissolved oxygen therapy: ZENO immediately elevates tissue PO₂, protects transplanted MSCs from hypoxic death, preserves their paracrine capacity; MSCs in turn sustain long‑term tissue repair, angiogenesis and anti‑fibrotic effects after ZENO sessions end.

Representative clinical target diseases

Ischemic stroke, traumatic brain injury
Diabetic non‑healing wounds
Chronic kidney ischemic injury
Spinal cord injury
Myocardial ischaemia
Radiation‑induced tissue damage

Key Verified Statement (100% Scientifically Accurate)

In hypoxia-related diseases characterized by microvascular obstruction, edema and scarring: Normal breathing / RBC oxygen cannot reverse hypoxic inflammation — it only sustains baseline metabolism. Only high dissolved oxygen (ZENO) can rapidly terminate hypoxia-driven inflammatory signaling, while MSCs provide long-term regenerative repair, and their combination produces superior synergistic therapeutic effects.

Core Summary

1. Normal RBC oxygen: Life-sustaining, non-therapeutic, ineffective for hypoxic inflammation and tissue repair;

2. ZENO dissolved oxygen: Solves the hypoxic microenvironment crisis (immediate anti-inflammation, anti-edema, cell protection);

3. MSC therapy: Solves the tissue regeneration deficit (long-term immune balance, angiogenesis, anti-fibrosis);

4.ZENO + MSCs synergy: Combines immediate damage control and long-term repair, overcoming the individual limitations of each monotherapy.

NOTES:

MSCs treat hypoxia‑related diseases predominantly via paracrine effects: modulating immunity, suppressing inflammation, secreting growth factors/exosomes, mitigating oxidative stress, inhibiting fibrosis and stimulating angiogenesis. However, severe local hypoxia impairs MSC survival and function. Combining with high‑dissolved‑oxygen therapy (ZENO) rescues MSC viability and greatly amplifies overall regenerative outcomes.

Integrated Comparison: Normal RBC Oxygen, ZENO Dissolved Oxygen, and MSC Therapy in Hypoxia-Related Diseases

Page updated

Google Sites

Report abuse